Health
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to the body of evidence supporting this potential treatment option.1 Four abstracts in total were presented, highlighting a breadth of results with oral semaglutide 25 mg during ObesityWeek® 2025 in Atlanta, GA.
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associated with improvements in blood sugar control and cardiovascular (CV) risk factors across multiple categories of weight loss1","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"Another analysis detailed an indirect trial comparison between oral semaglutide 25 mg and the currently available injectable form, showing comparable efficacy2","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"In two additional analyses, oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively3,4","length":232,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":608,"olType":false},{"type":"text","content":"PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 5, 2025 /PRNewswire/ -- Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to the body of evidence supporting this potential treatment option.1 Four abstracts in total were presented, highlighting a breadth of results with oral semaglutide 25 mg during ObesityWeek® 2025 in Atlanta, GA.","length":408,"tagName":"p"},{"type":"text","content":""Novo Nordisk has pioneered innovation in the obesity class for 25 years, and the oral semaglutide data at ObesityWeek® reflect our drive to improve the lives of people living with obesity," said Martin Holst Lange, chief scientific officer and executive vice president of Research & Development at Novo Nordisk. "The OASIS 4 results that we are sharing at this important meeting build on existing clinical trial evidence for oral semaglutide and extend findings beyond weight loss to suggested improvements in overall health."","length":551,"tagName":"p"},{"type":"text","content":"A cardiometabolic post hoc analysis from the OASIS 4 phase 3 clinical trial examined how the amount of weight patients lost affects glycemic parameters (blood sugar control) and cardiovascular (CV) risk factors in adults with overweight and obesity. In participants with overweight or obesity, once-daily oral semaglutide 25 mg treatment compared with placebo led to greater improvements in glycemic para...